Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study
André Lacroix, Marcello D. Bronstein, Jochen Schopohl, Tuncay Delibaşı, Roberto Salvatori, Yu Li, Ariel Barkan, Noriyuki Suzaki, Libuse Tauchmanovà, C.-E. Ortmann, S. Ravichandran, Stephan Petersenn, Rosario Pivonello
Topics & Concepts
PasireotideCushing's diseaseMedicineQuality of life (healthcare)DiseasePhase (matter)Phases of clinical researchPediatricsInternal medicineAcromegalyClinical trialChemistryHormoneGrowth hormoneNursingOrganic chemistryPituitary Gland Disorders and TreatmentsAdrenal Hormones and DisordersAdrenal and Paraganglionic Tumors